Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 4/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL438476 | 0.89 | NR1H4 (0.58) | APEX1NR1H4HPGDSMN1; SMN2LMNA | |
| SCHEMBL436249 | 0.84 | HPGD (0.51) | APEX1NR1H4HPGDSMN1; SMN2LMNA | |
| SCHEMBL30740970 | 0.77 | LCK (0.56) | HPGDSMN1; SMN2ALDH1A1MAPTPKM | |
| SCHEMBL437132 | 0.77 | LCK (0.56) | HPGDSMN1; SMN2ALDH1A1MAPTPKM | |
| SCHEMBL451070 | 0.76 | HDAC1 (0.64) | — | |
| SCHEMBL16127866 | 0.73 | APEX1 (0.71) | APEX1NR1H4HPGDALDH1A1KMT2A | |
| SCHEMBL10397102 | 0.72 | TUBB4A (0.56) | APEX1SMN1; SMN2LMNAALDH1A1KMT2A | |
| SCHEMBL9198418 | 0.72 | TUBB4A (0.56) | SMN1; SMN2LMNAALDH1A1KMT2AMAPT | |
| SCHEMBL16135579 | 0.72 | ALDH1A1 (0.54) | APEX1HPGDSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL10397857 | 0.70 | PPARG (0.58) | HPGDSMN1; SMN2LMNAALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716326-B2 | Isoindolinone derivatives, preparation method thereof and a pharmaceutical composition comprising same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2014-05-06 | — | — | US | disclosed |
| EP-2429987-A2 | AMIDE COMPOUND, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Korea Research Institute Of Chemical Technology (KR) | 2012-03-21 | — | — | EP | disclosed |
| US-20120065396-A1 | ISOINDOLINONE DERIVATIVES, PREPARATION METHOD THEREOF AND A PHARMACEUTICAL COMPOSITION COMPRISING SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-03-15 | — | — | US | disclosed |
| WO-2010131922-A2 | AMIDE COMPOUND, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065396-A1 | ISOINDOLINONE DERIVATIVES, PREPARATION METHOD THEREOF AND A PHARMACEUTICAL COMPOSITION COMPRISING SAME | PPIP5K2, SOST, ALPL | APEX1 241/4885NR1H4 2524/4885HPGD 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.